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INTRODUCTION 
 
Ferroptosis is a newly discovered form of cell death 
characterized by iron-dependent lipid peroxidation [1]. 
Ferroptosis is closely related to metabolism of amino 
acids, iron and polyunsaturated fatty acids, and 
biosynthesis of glutathione, phospholipids, NADPH, 
and coenzyme Q10 [2, 3]. Ferroptosis is inhibited by 
iron chelators, lipid peroxidation inhibitors, and 
reduction of intracellular polyunsaturated fatty acids 
[2]. Preliminary evidence suggests that ferroptosis 
suppresses tumor growth and progression and is 
potentially beneficial for cancer therapy [3]. However, 
the relationship between expression of ferroptosis- 
 
related genes (FRGs) and tumorigenesis has not been 
investigated in detail. 
 
In this study, we systematically analyzed the 
differential expression and genetic alterations in 
ferroptosis-related genes (FRGs) in 32 cancer types. 
We focused on clear cell renal cell carcinoma (ccRCC) 
for several reasons. The cytoplasm of ccRCC cells is 
rich in lipids [28].  
 
A recent study showed that aerobic glycolysis was 
significantly upregulated in ccRCC compared to glioma 
and lung cancer [4]. The glycolytic metabolites are 
precursors for the synthesis of fatty acids [28, 29].  
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In this study, we analyzed the clinical significance of ferroptosis-related genes (FRGs) in 32 cancer types in 
the GSCA database. We detected a 2-82% mutation rate among 36 FRGs. In clear cell renal cell carcinoma 
(ccRCC; n=539) tissues from the The Cancer Genome Atlas database, 30 of 36 FRGs were differentially 
expressed (up- or down-regulated) compared to normal kidney tissues (n=72). Consensus clustering analysis 
identified two clusters of FRGs based on similar co-expression in ccRCC tissues. We then used LASSO 
regression analysis to build a new survival model based on five risk-related FRGs (CARS, NCOA4, FANCD2, 
HMGCR, and SLC7A11). Receiver operating characteristic curve analysis confirmed good prognostic 
performance of the new survival model with an area under the curve of 0.73. High FANCD2, CARS, and 
SLC7A11 expression and low HMGCR and NCOA4 expression were associated with high-risk ccRCC patients. 
Multivariate analysis showed that risk score, age, stage, and grade were independent risk factors associated 
with prognosis in ccRCC. These findings demonstrate that this five risk-related FRG-based survival model 
accurately predicts prognosis in ccRCC patients, and suggest FRGs are potential prognostic biomarkers and 
therapeutic targets in several cancer types.    
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Furthermore, aerobic glycolysis, which is an hallmark 
of cancer cells, is necessary for the robust production of 
fatty acids that are required for the rapid proliferation 
and progression of tumor cells [5]. Ferroptosis is also 
triggered by perturbations in lipid metabolism [3]. 
Therefore, we analyzed the status of expression of 
FRGs in ccRCC. We also constructed a new survival 
model with five risk FRGs using Lasso regression 
analysis and verified its prognostic significance in 
ccRCC.  
 
RESULTS AND DISCUSSION  
 
Widespread genetic alterations of FRGs in 32 cancer 
types 
 
We performed a comprehensive literature survey [1–3, 
6–16] and identified 36 key ferroptosis-related proteins 
(Figure 1A). Figure 1B shows the protein-protein 
interactions (PPI) network analysis between these 36 
ferroptosis-related proteins using the STRING online 
database (https://string-db.org) and visualized with 
the Cytoscape software [17]. We then used the GSCA 
database [18] to determine the single nucleotide 
variations (SNV) and copy number variations (CNV) in 
the 36 FRGs in the 32 cancer types. Our analysis 
revealed that TP53, NFE2L2, FANCD2, DPP4, ALOX5, 
PTGS2, ALOX15B, ACSL4, CARS, HMGCR were the 
top 10 FRGs with mutation rates ranging from 2–82% 
(Supplementary Figure 1A). The average mutation rate 
of TP53 was the highest among all FRGs at 82%; 
majority of the genetic aberrations were missense 
mutations and were more common in lung 
adenocarcinoma (LUAD) and squamous cell 
carcinoma(LUSC) (Supplementary Figure 1A, 1B). We 
also analyzed the CNVs in the FRGs among the 32 
cancer types and found heterozygous mutations in TP53 
and ALOX15B and heterozygous amplifications in RPL8 
and PTGS2 (Supplementary Figure 1C). Then, to verify 
these results, we downloaded the raw CNV and SNV 
data of the 32 tumors from the TCGA database, 
analyzed using the Perl and R languages, and visualized 
the results using TBtools [19]. These results were 
consistent with those from the GSCALite website 
(Figure 1C, 1D). 
 
Prognostic significance of FRGs in various tumors 
 
Next, we analyzed the prognostic relevance of FRGs in 
different tumors. The mRNA expression data analysis 
of tumor data from the TCGA database for 32 tumors 
using the R language and TBtools software showed that 
SLC7A11, a representative FRG, was up-regulated in all 
32 different tumors compared to the corresponding 
controls (Figure 2B). Furthermore, TIMER database 
[20] analysis also showed that SLC7A11gene 
expression was significantly upregulated in 32 tumor 
tissues compared to the corresponding normal tissues 
(Figure 2A). We also analyzed the levels of 18 
ferroptosis-related proteins in ccRCC tissues using the 
UALCAN database [21] and found significant 
upregulation of ferroptosis-related proteins in the 
ccRCC tumor tissues compared to the controls (Figure 
2C). UALCAN now provides protein expression 
analysis option using data from Clinical Proteomic 
Tumor Analysis Consortium (CPTAC) Confirmatory/ 
Discovery dataset. The protein expression for Colon 
cancer, Breast cancer, Ovarian cancer, Clear cell renal 
cell carcinoma and Uterine corpus endometrial 
carcinoma is available [30]. 
 
Next, we analyzed the relationship between the 
expression of FRGs and the overall survival (OS) in 33 
different kinds of tumors using the GEPIA online 
database [22]. The results varied in different tumors. 
For example, in ccRCC, high expression of MT1G, 
CHAC1, and ALOX5, as well as low expression of the 
remaining 33 FRGs correlated with significantly lower 
OS; conversely, low ALOX5 expression correlated with 
reduced OS in Bladder Urothelial Carcinoma (BLCA), 
Cholangiocarcinoma (CHOL), and Skin Cutaneous 
Melanoma (SKCM) (Figure 2D). 
 
Functional analysis of FRG-related pathways in 
ccRCC 
 
The critical role of the Warburg effect and lipid 
metabolism has been well established in ccRCC [3–5]. 
Since ferroptosis also involves lipid metabolism, we 
analyzed the expression of FRGs in 72 normal kidney 
and 539 ccRCC specimens from the TCGA database 
use Limma package by R language. The results showed 
that 30 out of 36 FRGs (Supplementary Table 1) were 
differentially expressed in ccRCC tissues compared to 
the normal kidney tissues (Figure 3A). We observed 
strong correlation among the FRGs, with GCLC and 
NCOA4 showing a Pearson correlation co-efficient of 
0.52 (Figure 3B). Furthermore, we performed gene 
integration analysis [23–25] to determine the relationship 
between FRGs and other genes in ccRCC. Protein-protein 
interaction (PPI) network analysis using the STRING 
website showed a strong interaction network among the 
36 FRG and 30 FRG-related genes (Supplementary Table 
2). The heatmap showed that the expression of these 16 
genes(MT1G, CHAC1, ACSL, AKR1C2, PTGS2, 
AKR1C1, CBS, FDFT1, HMGCR, ATP5MC3,  
GLS2, NFE2L2, CS, NCOA4, CISD1, GSS) in ccRCC 
tissues was significantly down-regulated and 45 genes 
(EMC2, RPL21, RPS12, GCLM, RPL7, FANCD2, 
RPS3A, TP53, RPL5, GPX4, RPS10, RPL3, RPL10A, 
RPS4X, RPL17, RPS13, RPS17, DPP4, RPL23, 
AKR1C3, RPL19, RPS7, RPS27, RPS25, RPL8, RPS24, 
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Figure 1. Genetic alterations and PPI network of 36 FRGs in the TCGA pan-cancer datasets. (A) Diagrammatic representation 
shows intracellular localization of ferroptosis-related proteins in different signaling pathways. (B) The protein-protein interaction network 
analysis results of 36 ferroptosis-related genes (FRGs) are shown. (C) The copy number variation (CNV) frequency of the 36 FRGs is shown for 
the 32 cancer types. The color code bar on the right refers to differential gain or loss of copy numbers. (D) The single nucleotide variation 
(SNV) frequency of the 36 FRGs is shown for the 32 cancer types. The color code bar on the right refers to differential SNV frequencies.  
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RPL11, RPS16, HSPB1, CARS, RPL23A, RPS11, 
RPS18, RPS5, RPS28, CRYAB, RPS8, RPS20, RPS14, 
RPL18A, ALOX12, RPS19, SLC7A11, ALOX5, 
ALOX15B) was significantly up-regulated compared to 
the normal kidney tissues (Figure 3C). GO functional 
analysis of these 66 FRGs and FRG-related genes 
showed them linked to pathways such as SRP-
dependent co-translational protein targeting to 
membrane, co-translational protein targeting to 
membrane protein targeting to ER, nuclear-transcribed 
mRNA catabolic process, and nonsense-mediated decay 
(Figure 3D, 3E; Supplementary Table 3). KEGG 
pathway analysis showed that these 66 genes were 
involved in pathways related to ferroptosis, ribosome 
metabolism, arachidonic acid metabolism, glutathione 
metabolism, cysteine and methionine metabolism, and 
serotonergic synapse (Figure 3F; Supplementary Table 
4). Furthermore, we analyzed the GSLA database to 
determine the role of FRGs in different classical 
signaling pathways in ccRCC. The results showed that 
the expression of FRGs was related to the activation or 
inhibition of multiple oncogenic pathways; for example, 
FANCD2 expression correlated with the activation of 
apoptotic, cell cycle, and EMT pathways; AKR1C2 
expression correlated with the inhibition of apoptotic 
and DNA damage response pathways (Supplementary 
Figure 2).  
 
Consensus clustering analysis of FRGs reveals two 
clusters in ccRCC 
 
Next, we used the commonclusterplus package to 
identify the different groups of FRGs based on their co-




Figure 2. Pan-cancer mRNA and protein expression of FRGs. (A) Box plots show SLC7A11 mRNA expression in tumor (red) and normal 
(blue) tissue samples corresponding to 33 cancer types. Note: **P<0.01; ***P<0.001. (B) Alterations in the expression of 36 FRGs in 20 
different cancer types are shown with the color code bar (right) referring to the corresponding log2 (FC) values. (C) Box plots show the 
differences in the expression of 18 different ferroptosis-related proteins in the KIRC (blue) and normal kidney (orange) tissues from the 
UALCAN dataset. (D) The overall survival of patients belonging to 33 cancer types based on the expression of the 36 FRGs is shown. The color 
code is shown in the right. 
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database. We divided the FRGs into two groups based 
on their expression indices using k = 2 as the optimal 
value because the grouping was suboptimal when they 
were divided into more than 2 clusters (Figure 4A–
4C). The principal component analysis (PCA) 
confirmed the clustering results of FRGs into two 
subgroups (Figure 4D). Next, we analyzed the 
relationship between these two clusters and the 
clinicopathological characteristics of ccRCC patients. 
In cluster 1, RPL8, GPX4, AKR1C3, CISD1, 
ATP5MC3, GSS, and HSPB1 showed significantly 
lower expression in ccRCC tissues, but the remaining 
cluster1 genes showed significantly higher expression 




Figure 3. Correlation and functional pathway analysis of FRGs and FRG-related proteins in ccRCC. (A) The expression of 36 FRGs 
in ccRCC patient samples is shown. The upregulated FRGs are indicated in red and the downregulated FRGs are shown in blue. N represents 
tumor sample, T represents normal sample. (B) Co-expression analysis shows the correlation between the 36 FRGs based on their expression 
in ccRCC tissues. (C) The expression of 36 FRGs and 30 FRG-interacting proteins in ccRCC is shown with 72 normal kidney tissues and 539 
tumor tissues. (D, E) GO terms representing biological processes for the 66 FRGs and FRG-interacting genes. (F) KEGG pathway analysis shows 
the main signaling pathways represented by the 66 FRGs and FRG-interacting genes. Note: *P < 0.05, **P < 0.01. ***P < 0.001.  
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On the other hand, the expression of cluster 2 genes 
correlated with higher tumor grades, stage, and the M- 
and T-stage (TNM staging) tumors (Figure 2E). 
Therefore, these results demonstrate that the expression 
of FRGs is closely related to tumor malignancy and 
progression in ccRCC patients (Figure 2E). 
Construction and verification of the new FRG-based 
survival model  
 
To better understand the prognostic role of FRGs in 
ccRCC, we performed a univariate Cox regression 




Figure 4. Consensus clustering analysis of FRGs in ccRCC. (A) The heat maps show the consensus clustering matrix for FRGs in the 
ccRCC dataset for k = 2, 3, 4 and 5. The optimal clustering is represented by k=2. (B) The cumulative distribution function (CDF) plot of 
consensus clustering matrix for k=2–9 is shown. (C) The consensus CDF plots show the cumulative distributive functions of the consensus 
matrix for k values (indicated by different colors) between 2 and 9. (D) Principal component analysis (PCA) of FRGs mRNA expression profiles 
of the ccRCC patients in the TCGA dataset demonstrates two patient clusters, cluster1 (in red) and cluster2 (in blue). (E) Heatmap shows the 
correlation between the expression of FRGs and the clinicopathological features of the two ccRCC patient clusters, cluster 1 (orange) and 
cluster 2 (green). The color codes for different clinicopathological parameters are as indicated. The expression of FRGs is also indicated by a 
color code bar, where red refers to high expression or upregulation and green refers to low expression or downregulation.  
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dataset. The results indicated that high expression of 
CARS, FANCD2, SLC7A11, CHAC1, SAT1, CBS, 
ALOX15, and AKR1C2 correlated with worse survival 
rates in patients with ccRCC. In contrast, high 
expression of NCOA4, HMGCR, DPP4, GCLC, 
FDFT1, LPCAT3, GCLM, and NFE2L2 correlated with 
better survival rates in ccRCC patients (Figure 5A; 
Supplementary Table 5). We first selected FRGs as 
survival-related FRGs according to the P-value < 0.05, 
and then used the LASSO regression model to analyze 
and determine the most powerful prognostic markers, 
based on the results, we selected five genes (CARS, 
NCOA4, FANCD2, HMGCR, SLC7A11) to build a risk 
signature model based on minimum criteria (Figure 5B, 
5C). Then, we divided the ccRCC patients into low- and 
high-risk groups based on the median risk score and 
investigated the prognostic prediction performance of 
the new survival model made up of five genetic risk 
characteristics. Kaplan-Meier survival curve analysis 
showed that the high-risk group patients had 
significantly lower survival rates than the low-risk 
group patients (Figure 5D). Furthermore, we performed 
ROC curve analysis to analyze the prognostic prediction 
performance of the new survival model in ccRCC 
patients and obtained a AUC score of 0.73, thereby 
demonstrating that the risk score calculated by this 
model can accurately predict the 5-year survival rate of 




Figure 5. Construction of FRG-based survival model for prognostic prediction in ccRCC. (A) Univariate Cox regression analysis 
results show the hazard ratios (HR) with 95% confidence intervals (CI) and p values for the 36 FRGs. (B, C) Risk score model 
construction for FRGs using Lasso regression analysis. (B) Partial likelihood deviance was plotted against log (lambda). The 
vertical dotted lines indicate the lambda value with minimum error. The largest lambda value is where the deviation is within 
one standard error (SE) of the minimum. (C) The Lasso coefficient profiles of FRGs in ccRCC. (D) Kaplan–Meier survival curves 
show overall survival of high- and low-risk ccRCC patients that are grouped according to the risk scores calculated by the new 
survival model based on the expression of 5 FRGs. (E) ROC curve analysis shows the prognostic prediction efficiency of the new 
survival model. As shown, the AUC value for the new survival model is 0.73. 
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Figure 6. Relationship between the risk score, clinicopathological features. (A) The heatmap shows the profiles of the expression of 
survival model FRGs and clinicopathological features in low- and high-risk ccRCC patients. (B) Diagrammatic representation shows the 
regulatory relationship between transcription factors and FRGs. The red lines represent positive regulation, the blue lines represent reverse 
regulation, the yellow triangle represents transcription factors, the red oval represents up-regulated FRGs, the green oval represents down-
regulated FRGs, and gray represents statistically insignificant ERGs. (C) Univariate Cox regression analyses results show the association 
between clinicopathological parameters such as age, gender, grade, tumor size (T), tumor node (N), tumor metastasis (M), and risk score of 
the new survival model with the OS of ccRCC patients. (D) Multivariate Cox regression analyses results show the association between 
clinicopathological parameters such as age, gender, grade, tumor size (T), tumor node (N), tumor metastasis (M), and risk score of the new 




Figure 7. Experimental verification of CARS. (A–C) Immunohistochemical images from the HPA database show CARS protein expression 
in ccRCC (T) and normal kidney (N) tissues. (D) CCK8 assay results show the relative proliferation of si-control- and si-CARS-transfected 786-O 
cells. The data are shown as means ± S.D. 
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The new FRG-based survival model shows strong 
association with clinicopathological features of 
ccRCC patients 
 
To better understand the relationship between FRGs and 
ccRCC, we systematically analyzed correlation between 
the risk score based on the expression of five FRGs, 
namely, FANCD2, HMGCR, SLC7A11, CARS and 
NCOA4 and the clinicopathological characteristics of high- 
and low-risk ccRCC patients in the TCGA dataset. We 
observed a strong correlation between the risk score and 
the clinicopathological characteristics such as T (tumor 
size), N (tumor node), M (tumor metastasis), tumor grade, 
tumor staging, gender, and survival in high- and low-risk 
ccRCC patients (Figure 6A). In the high-risk group, 
FANCD2, CARS, and SLC7A11 levels were significantly 
up-regulated, whereas HNGCR and NCOA4 levels were 
significantly down-regulated (Figure 6A). COX regression 
analysis showed that risk score, grade, age, tumor stage, 
tumor size (T), and tumor metastasis (M) correlated with 
the OS of ccRCC patients (Figure 6C; Supplementary 
Table 6). Multivariate COX regression analysis showed 
that risk score, age, stage, and grade were independent risk 
factors for the prognosis of ccRCC patients (Figure 6D. 
Supplementary Table 7). Finally, we showed strong 
correlation between several transcription factors and FRGs 
and established a regulatory network among them (Figure 
6B). Next, we used CARS gene to verify our model. The 
Human Protein Atlas database analysis shows that CARS 
expression is significantly higher in ccRCC tissues 
compared to normal kidney tissues Figure 7A–7C [26]. 
These results were consistent with previous bioinformatics 
analysis results (Figures 2B, 2C, 3A). CCK8 proliferation 
assay shows that CARS knockdown 786-O cells showed 
significant reduction in proliferation compared to the 
control 786-O cells (Figure 7D). This suggests that CARS 
may play an oncogenic role in ccRCC, but the specific 
mechanism needs to be investigated further. 
 
In conclusion, we systematically showed the clinical 
relevance of FRGs in 32 cancer types. Furthermore, 
bioinformatics analysis of FRGs in clear cell renal cell 
carcinoma (ccRCC) demonstrated that the expression of 
FRGs correlates with several clinicopathological 
characteristics of ccRCC patients including tumor stage, 
grade, T- and M-stages. We further constructed and 
verified a survival model using five FRGs to predict the 
prognosis of ccRCC patients.  
 
MATERIALS AND METHODS 
 
Cell lines, siRNA knockdown, antibodies and 
reagents  
 
The human ccRCC cell lines 786-O cells were 
purchased from the Cell Bank of the Chinese Academy 
of Sciences. All cells were cultured according to the 
manufacturer's protocol. 786-O cells were cultured in 
RPMI 1640 medium containing 10% foetal bovine 
serum, cells were cultured at 37 °C with 5% CO2. cells 
were transfected with 20 nmol/L siRNAs using 
Lipofectamine RNAiMAX reagent (Invitrogen).  
 
Data acquisition and analysis 
 
The SNV and CNV data of 32 cancers was downloaded 
from The Cancer Genome Atlas (https://cancerge 
nome.nih.gov/) database, analyzed using the Perl 
language and visualized with the TBtools software. The 
RNA-seq transcriptome data of the KIRC cohort was 
downloaded through the R/Bioconductor package 
TCGAbiolinks with 72 normal kidney tissues and 539 
tumor tissues [27] at the Genomic Data Commons 
(GDC) portal. We also downloaded gene expression, 
CNV and SNV data for 32 types of cancers as 
Fragments Per Kilobase of transcript per Million 
mapped reads (FPKM) at the Genomic Data Commons 
(GDC) portal. We totally analyzed 32 different TCGA 
projects, each project represents a specific cancer type, 
including kidney renal clear cell carcinoma (KIRC);  
kidney renal papillary cell carcinoma (KIRP); kidney 
chromophobe (KICH); brain lower grade glioma (LGG); 
glioblastoma multiforme (GBM); breast cancer (BRCA); 
lung squamous cell carcinoma (LUSC); lung 
adenocarcinoma (LUAD); rectum adenocarcinoma 
(READ); colon adenocarcinoma (COAD); uterine 
carcinosarcoma (UCS); uterine corpus endometrial 
carcinoma (UCEC); ovarian serous cystadenocarcinoma 
(OV); head and neck squamous carcinoma (HNSC); 
thyroid carcinoma (THCA); prostate adenocarcinoma 
(PRAD); stomach adenocarcinoma (STAD); skin 
cutaneous melanoma (SKCM); bladder urothelial 
carcinoma (BLCA); liver hepatocellular carcinoma 
(LIHC); cervical squamous cell carcinoma and 
endocervical adenocarcinoma (CESC);  adrenocortical 
carcinoma (ACC); pheochromocytoma and 
paraganglioma (PCPG); sarcoma (SARC); pancreatic 
adenocarcinoma (PAAD); esophageal carcinoma 
(ESCA); testicular germ cell tumors (TGCT); 
thymoma(THYM); uveal melanoma (UVM); lymphoid 
neoplasm diffuse large b-cell lymphoma (DLBC); 
cholangiocarcinoma (CHOL). The clinical information 
of cancer patients including information regarding age, 
survival status, tumor grades, tumor stages, tumor size 
(T) status, and metastasis (M) status was downloaded 
from TCGAbiolinks and analyzed with the Perl 
language and R studio. The expression data of FRGs in 
539 ccRCC and 72 normal kidney tissues was analyzed 
with the Limma package and visualized as a heat map 
using the TBtools software. Coexpression analysis was 
performed using the “Corrplot” package. We used the 
“Consensus Cluster Plus” package to determine the 
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gene clusters, and then used “Ggplot2” and “Limma” 
package for PCA analysis. We performed LASSO 
regression analysis with the “Glmnet” and “Survival” 
packages. The univariate and multivariate Cox hazard 
analysis of clinical characteristics was performed by 
"survival" package.  
 
Establishment of regression model and construction 
of risk score 
 
After removing the samples without complete clinical 
information, univariate Cox models were performed to 
investigate the correlation between the FRGs expression 
levels and the overall survival (OS) in KIRC patients. We 
first selected FRGs as survival-related genes according to 
the P-value < 0.05. Then, Lasso regression was performed 
to eliminate genes that might overfit the model. Lastly, we 
applied multivariate analysis to identify the optimal 
prognostic FRGs for the model. The risk score was 
calculated based on a linear combination of the Cox 
coefficient and gene expression. The following 
calculation formula was used for the analysis: Risk score 
=Σ Ni=1 (Expi*Coei). N, Coei, and Expi represented gene 
number, coefficient value, and level of gene expression, 
respectively. The median was set as the cut-off value to 
divided all KIRC patients into low-risk and high-risk 
groups. Time-dependent receiver operating characteristic 
(ROC) analysis for overall survival (OS) was used to 
evaluate the accuracy of the prognostic model.  
 
Analysis of genome alterations and cellular 
pathways and GEPIA database 
 
GSCALite (http://bioinfo.life.hust.edu.cn/web/GSCA 
Lite/) database was used to analyze SNV and CNV of 
FRGs in 33 tumors. GSCALite database were also used 
to analyze the degree of FRGs activation or inhibition 
of the classical pathway. We used the Gene Expression 
Profiling Interactive Analysis (GEPIA) database to 
analyze the OS of patients belonging to 33 tumor types 
based on the expression of FRGs. cutt-off high value 
and low value is set to 50%. P <0.05 was considered 
statistically significant.  
 
Protein-protein interaction network  
 
Protein-Protein Interaction (PPI) network analysis of 
DEGs was performed using the STRING database, and 
functional networks were identified with a medium 
confidence score of more than 0.4 and other default 
parameters.  
 
TIMER and UALCAN analysis 
 
The TIMER online tool was used to analyze the 
expression of the SLC7A11 gene in different tumors. 
The UALCAN online tool is used to analyze the levels 
of ferroptosis-related proteins in 110 kidney renal clear 
cell carcinoma (KIRC) and 84 normal kidney tissues. 
UALCAN now provides KIRC protein expression 
analysis option using data from CPTAC dataset (84 
normal tissues and 110 renal tumor tissues).  
 
CCK8 cell proliferation assay 
 
We cultured 1×103 786-O cells per well in 96-well 
culture plates for 5 days (4 replicate wells per group). 
Cell Counting Kit 8 (Dojindo, Japan) was used 
according to the manufacturer’s instructions. Then, we 
added 10 µL CCK-8 reagent (Dojindo, Japan) to each 
well and incubated cells for further 1-2 h. Then, we 
determined the optical density (OD) of each well at 450 
nm using a microplate reader. 
 
Statistical analyses  
 
One-way ANOVA was used to compare the expression 
of FRGs in tumor and normal tissue samples. The 
Student’s t-test was used to compare the expression of 
FRGs in the KIRC dataset according to gender, age, 
stage, T (tumor size), and M (tumor metastasis) status. 
N (tumor node) status was not included in the study 
because it was not verified for a large number of 
samples in the TCGA database. The cut-off value of 
each risk score in the tumor group was determined 
using the “survminer” package, and the patients were 
divided into high- and low-risk groups according to the 
best cut-off threshold value. R studio package was used 





CNV: Copy number variation; KIRC: Kidney renal 
clear cell carcinoma; UCEC: Uterine corpus 
endometrial carcinoma; ccRCC: Clear cell renal cell 
carcinoma; FRGs: Ferroptosis-related genes; PPI: 
Protein-protein interaction; SNV: Single nucleotide 
variation; PCA: Principal component analysis; LUAD: 
lung adenocarcinoma; LUSC: squamous cell carcinoma; 
CPTAC: Clinical Proteomic Tumor Analysis 
Consortium; OS: overall survival; BLCA: Bladder 
Urothelial Carcinoma; CHOL: Cholangiocarcinoma; 
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Supplementary Figure 1. Pan-cancer genetic alterations of FRG. (A, B) The mutation frequency of FRG across 32 cancer types. (C) The 














Supplementary Figure 2. Pathway analysis of FRG. Network diagram demonstrating the correlation between FRG and cancer 
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Supplementary Tables 
 
Please browse Full Text version to see the data of Supplementary Tables 1 to 5. 
 
Supplementary Table 1. The expression of FRGs in ccRCC and normal kidney tissues from the TCGA database.  
Supplementary Table 2. A list of 66 FRGs and FRG-related genes by string. 
Supplementary Table 3. Summary of GO pathway analysis results of FRGs.  
Supplementary Table 4. Summary of KEGG pathway analysis results of FRGs. 
Supplementary Table 5. Univariate Cox regression analysis of the prognostic significance of the expression of FRGs in 
ccRCC samples from the TCGA dataset  
Supplementary Table 6. Univariate analysis of risk score and other KIRC clinical data.  
id HR HR.95L HR.95H pvalue 
age 1.029049 1.015526 1.042753 2.21E-05 
gender 0.953475 0.693387 1.311121 0.769403 
grade 2.303129 1.870932 2.835165 3.62E-15 
stage 1.900087 1.659546 2.175493 1.48E-20 
T 1.934057 1.634871 2.287994 1.44E-14 
M 4.509619 3.290467 6.180481 7.51E-21 
riskScore 1.172773 1.128116 1.219197 8.55E-16 
 
Supplementary Table 7. Multivariate regression analysis of risk score and other KIRC clinical data.  
id HR HR.95L HR.95H pvalue 
age 1.034601 1.019246 1.050187 8.25E-06 
gender 0.95717 0.690262 1.327283 0.792975 
grade 1.478108 1.170279 1.866907 0.001039 
stage 1.819611 1.151655 2.874979 0.010318 
T 0.766397 0.503673 1.166164 0.214151 
M 1.269594 0.639759 2.519492 0.49485 
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Supplementary Table 8. Regulatory relationship between transcription factors and FRGs 
TF FRGs cor pvalue Regulation 
BATF FANCD2 0.424352 2.09E-24 postive 
CEBPA ALOX5 0.430824 3.49E-25 postive 
CEBPB NCOA4 -0.40479 3.70E-22 negative 
CENPA CARS 0.444214 7.59E-27 postive 
CENPA FANCD2 0.760034 3.86E-100 postive 
CENPA CBS 0.490092 3.93E-33 postive 
CIITA ALOX12 0.417909 1.19E-23 postive 
E2F1 FANCD2 0.584767 1.43E-49 postive 
EOMES FANCD2 0.423908 2.36E-24 postive 
ETS1 GSS -0.47768 2.45E-31 negative 
ETS1 GPX4 -0.49883 1.93E-34 negative 
ETS1 HSPB1 -0.45975 7.20E-29 negative 
EZH2 FANCD2 0.749936 4.24E-96 postive 
FLI1 GSS -0.45969 7.33E-29 negative 
FLI1 GPX4 -0.45103 1.01E-27 negative 
FLI1 ATP5MC3 -0.43823 4.29E-26 negative 
FOXM1 CARS 0.466305 9.38E-30 postive 
FOXM1 TFRC 0.407549 1.82E-22 postive 
FOXM1 FANCD2 0.695871 2.29E-77 postive 
FOXM1 CBS 0.630685 1.10E-59 postive 
GATA2 CHAC1 0.43485 1.12E-25 postive 
GATA3 CBS 0.52576 1.01E-38 postive 
HEY1 GSS -0.41796 1.18E-23 negative 
HIF1A ACSL4 0.499759 1.39E-34 postive 
LMNB1 CARS 0.402936 5.94E-22 postive 
LMNB1 TFRC 0.414054 3.33E-23 postive 
LMNB1 FANCD2 0.750462 2.64E-96 postive 
MEF2C GSS -0.44669 3.67E-27 negative 
MEF2C GPX4 -0.45883 9.54E-29 negative 
MYBL2 CARS 0.460291 6.10E-29 postive 
MYBL2 FANCD2 0.702684 1.72E-79 postive 
MYBL2 CBS 0.443459 9.46E-27 postive 
MYC NFE2L2 0.417635 1.28E-23 postive 
NCAPG CARS 0.471307 1.92E-30 postive 
NCAPG TFRC 0.402843 6.09E-22 postive 
NCAPG FANCD2 0.774639 2.36E-106 postive 
NCAPG CBS 0.532948 6.24E-40 postive 
PBX1 NCOA4 0.428139 7.36E-25 postive 
PRDM1 GSS -0.42233 3.63E-24 negative 
PRDM1 GPX4 -0.43305 1.87E-25 negative 
PRDM1 ATP5MC3 -0.43383 1.50E-25 negative 
SREBF2 HMGCR 0.56739 3.80E-46 postive 
SREBF2 CS 0.504764 2.37E-35 postive 
SREBF2 FDFT1 0.492813 1.55E-33 postive 
VDR HMGCR 0.400825 1.02E-21 postive 
 
 
